ESR1 and breast cancer: Indeed, 25–30% of patients with early-stage breast cancer treated with selective ER modulators (SERMs) blocking the activity of ER, such as tamoxifen, are at risk of relapsing within 2–5 years or developing resistance to the drug with ongoing treatment [1,2,3,4,5].